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Rôle de la chirurgie vitro-rétinienne dans la prise en charge
des complications induites par la protonthérapie dans le
cadre du mélanome de l'uvée
Résumé
L'utilisation de faisceaux de protons accélérés dans le traitement des mélanomes de
l'uvée a été utilisée pour la première fois en Suisse (et par ailleurs en Europe) en 1984.
Depuis, la protonthérapie a constamment évolué avec des logiciels toujours plus
performants et précis pour devenir à l'heure actuelle le traitement de référence pour ce
type de tumeurs. Ainsi, jusqu'à ce jour, l'lnstitut Paul Scherrer à Villigen a traité plus de
7000 cas de tumeurs oculaires.
Mais la protonthérapie, aussi efficace soit-elle avec un taux de guérison de plus de 9Bo/0,
comporte malheureusement un certain nombre d'effets secondaires et indésirables
pouvant parfois mener le patient jusqu'à l'énucléation secondaire. De la simple
dermatite actinique à l'hémorragie intravitréenne massive, les complications induites
sont pour Ia plupart bien connues et documentées mais leurs prises en charge,
notamment sur un organe préalablement irradié diffèrent. Alors que nous avons
beaucoup de recul sur la protonthérapie, la gestion de ses complications reste propre à
chaque centre de soin et n'est que très peu documentée.
Les complications majeures de la protonthérapie qui ont nécessité une prise en charge
par le chirurgien vitrorétinien représentent souvent un défi majeur. Bien que rares,
puisqu'elles ne représentent que 2o/o de notre collectil celles-ci peuvent avoir de lourdes
ðonséquences. Par exemple, une hémorragie intravitréenne massive, complication la
plus fréquente dans notre série, compromet l'observation de la tumeur au fond d'æil et
empêche le bon suivi oncologique.
La chirurgie vitrorétinienne a alors pour mission, de restaurer la transparence des
milieux, élément indispensable à l'ophtalmologue pour le suivi clinique, iconographique
et radiologique des mélanomes de l'uvée. Secondairement, cette chirurgie permet
parfois d'augmenter l'acuité visuelle de l'ceil malade.
La chirurgie vitrorétinienne est un précieux atout pour I'oncologue et permet d'éviter
une énucléation secondaire. Elle participe ainsi à la prise en charge globale du patient
atteint de mélanome de l'uvée.
ROLE OF VITREORETINAL SURGERY IN
MAXIMIZING TREATMENT OUTCOME
FOLLOWING COMPLICATIONS AFTER
PROTON THERAPY FOR UVEAL
MELANOMA
BAO-KHANH TRAN, MD, ANN SCHALENBOURG, MD, ETIENNE BOVEY, MD,
LEONIDAS ZOGRAFOS, MD, THOMAS J. WOLFENSBERGER, MD
Purpose: To assess the role of vitreoretinal surgery in maximizing treatment outcome
following complications after proton therapy for uveal melanoma and to evaluate its safety.
Methods: Retrospective chart study on 21 patients (2% of a total of 1,005 treated by
proton therapy between January 2003 and August 2007) who had developed a complication
requiring vitreoretinal surgery. Mean/median total follow-up after irradiation was 43/43
months (range, 12–70 months).
Results: Indications for surgery included vitreous hemorrhage (n = 13), epimacular mem-
brane (n = 5), rhegmatogenous retinal detachment (n = 1), combined vitreous hemorrhage
with total serous retinal detachment (n = 1), and vitritis (n = 1). Mean/median interval for
vitreoretinal surgery after irradiation was 21/20 months (range, 4–45 months), and mean/
median follow-up after pars plana vitrectomy was 22/23 months (range, 2–56 months). Pars
plana vitrectomy was combined with retinal photocoagulation (n = 5), air/gas (n = 5), or
silicone oil tamponade (n = 1). Mean Snellen visual acuity was 20/200 (0–20/40) before and
20/100 (0–20/25) after pars plana vitrectomy. A transient postoperative rise in intraocular
pressure was measured in seven patients. Four patients developed phthisis bulbi.
Conclusion: Vitreoretinal surgery was efﬁcient in maximizing treatment outcome after
proton therapy, as it allowed a better oncologic follow-up. Pars plana vitrectomy permitted
panretinal photocoagulation to avoid neovascular glaucoma or retinal detachment repair.
Macular surgery improved visual acuity, especially in anterior melanoma, whereas repeated
surgery may increase the risk of enucleation.
RETINA 33:1777–1783, 2013
Uveal melanoma (UM) is the most frequent intra-ocular malignancy in ophthalmologic practice,
mainly encountered in adult white populations with
an annual incidence of six new cases per million.1
Standard treatment is radiotherapy, using plaques or
proton beam, or enucleation with similar survival rates
for both methods.2 External proton beam radiotherapy
delivers a uniform irradiation to the target volume,
with a good sparing of uninvolved eye tissues. As
UM is a radioresistant tumor requiring high radiation
doses, proton therapy allows for tumors with a large
volume or a shape or location unﬁt for brachytherapy,
also being treated conservatively.3
The results of proton therapy ﬁgure among the best of
any conservative oncologic treatment techniques, with
local tumor recurrence only ranging from 1% to 5%.3
Eye retention rate varies from 85% to 100% and is
mainly related to tumor size, proximity to the disk,
and the extent of retinal detachment (RD) at treatment
time. The main cause of secondary enucleation is neo-
vascular glaucoma.3–5 Functional prognosis is often
From the Jules-Gonin Eye Hospital, University of Lausanne,
Lausanne, Switzerland.
Presented at the Club Jules-Gonin, XXVIIth Meeting, Kyoto,
Japan, November 6, 2010.
B.-K. Tran and A. Schalenbourg contributed equally to this
study.
None of the authors have any ﬁnancial/conﬂicting interests to
disclose.
Reprint requests: Thomas J. Wolfensberger, MD, Jules-Gonin Eye
Hospital, University of Lausanne, Avenue de France 15, Lausanne
CH-1004, Switzerland; e-mail: thomas.wolfensberger@fa2.ch
1777
poor, with a ﬁnal Snellen visual acuity of 20/100 in
,50% of the patients.6
Sight-threatening tumor and radiation-induced com-
plications include RD, maculopathy, papillopathy,
cataract, glaucoma, vitreous hemorrhage (VH), and
the recently described “toxic tumor syndrome.”7 Their
occurrence depends primarily on tumor location and
size. There are to date no precise data available on the
surgical management of vitreoretinal (VR) complica-
tions after proton therapy. The aim of this study was
therefore to assess the role of VR surgery in maximiz-
ing treatment outcome following complications after
proton beam irradiation for UM.
Patients and Methods
We scanned retrospectively through the data of
1,005 consecutive patients who were treated for UM
between January 2003 and August 2007. We identiﬁed
and investigated 21 patients/21 eyes (2%) that had
required VR surgery for a tumor or radiation-related
complication. All patients were seen at the Ocular
Oncology Unit of the Jules-Gonin Eye Hospital
(Lausanne, Switzerland), and investigations and treat-
ment included the following: conﬁrmation of UM
diagnosis, tantalum clip surgery, ophthalmic oncologic
follow-up, and VR surgery. Proton beam radiotherapy
was performed at the Paul Scherrer Institute (Villigen,
Switzerland), according to a standard protocol pre-
scribing 60 cobalt gray equivalent in 4 fractions on
4 consecutive days.8 Pars plana vitrectomy (PPV) was
performed according to the same standardized protocol
as for eyes without an intraocular tumor by two sur-
geons (E.B. and T.J.W.). In the cases presenting an
anterior ciliochoroidal tumor, the insertion of the
PPV instruments was planned in a manner as to avoid
the tumor site.
The mean age of our 21 patients (male to female
ratio: 12:9) at the time of melanoma diagnosis was
53 years (range, 19–69 years). The main outcome meas-
ures were indications for surgery, time interval after
proton therapy, and speciﬁc VR surgical modalities.
We also analyzed clinical follow-up data, including
Snellen best-corrected visual acuity, intraocular pres-
sure (IOP), and ﬁnal eye retention. The mean/median
total follow-up time after irradiation was 43/43 months
(range, 12–70 moths).
Results
Indications for VR surgery (Table 1) included VH
(n = 13), rhegmatogenous RD (n = 1), combined VH
with total serous RD (n = 1), vitritis of undetermined T
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origin (n = 1), and epimacular membrane (n = 5), 2 of
which were associated with a lamellar macular hole.
Indications for PPV were correlated with tumor loca-
tion, revealing that posterior melanomas tended to lead
more often to VH, whereas anterior melanomas were
associated more often with macular surgery. From
the 14 patients presenting a VH, 9 were presumed to
come from tumor vessels or retinal vessels overlying
a tumor with retinal invasion (of which the posterior
melanomas were originally called “Knapp-Ronne”
type melanoma9) (Figure 1), 3 were only associated
with ischemic retinopathy, and 2 cases presented both
complications. The former were treated with vitrec-
tomy only, in one case with coagulation of visible
tumor vessels, the others presumably having scarred
after radiotherapy. The latter ﬁve cases, presenting
proliferative radiation retinopathy, were at the end of
their PPV treated with panretinal photocoagulation and
one of them also with bevacizumab. This was the only
case that ultimately developed neovascular glaucoma.
Three of the ﬁve patients presenting VH and ischemia
had at the same time rubeosis iridis without glaucoma,
and in one of those three, the angle was involved.
The mean/median interval for the appearance of
these complications following proton therapy and
the subsequent VR surgery was 21/20 months (range,
4–45 months), with a mean/median follow-up time
after PPV of 22/23 months (range, 2–56 months).
Diagnosis was usually made after visual symptoms
had been noticed by the patient, although some com-
plications were only discovered during a routine onco-
logic follow-up examination.
Seven patients (33%) presented an anterior cilio-
choroidal tumor. Table 2 summarizes the variations
on standard PPV that were applied and the corre-
sponding number of patients. One patient with an
anterior melanoma and chronic inﬂammation had
a second vitrectomy to remove membranes provoking
pupillary seclusion around his lens implant. The three
other patients, having had repeated PPV because of
recurrent VH (average VH duration 4.5 months,
range, 3–6 months), ultimately all developed phthisis
Fig. 1. Panoramic fundus
pictures (Panoret camera) of
a VH after proton therapy of
a Knapp-Ronne type mela-
noma. A. A 55-year-old man
had a parapapillary, nasal cho-
roidal melanoma, presenting
a hemorrhage at its surface and
an invasion of the retina (white
arrows). Despite the presence
of a secondary serous RD, his
best-corrected visual acuity
(BCVA) was 20/25. He was
treated with proton therapy. B.
Six months later, his BCVA
had dropped to light percep-
tion, related to a VH. C. On
B-scan ultrasonography, the
VH was shown to originate
from the apex of the tumor,
which had regressed from an
original thickness of 8.4 mm to
7.8 mm. A simple uneventful
vitrectomy was performed. D.
Five months later, the tumor
scar remained perfectly visible,
with a BCVA at 20/400,
related to retinal atrophy.
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bulbi. No internal tumor resection was performed in
this series.
Pars plana vitrectomy and phacoemulsiﬁcation were
combined in 3 cases (14%) during the ﬁrst and in 2
cases (10%) during the second vitrectomy, when lens
opacities were too signiﬁcant to allow correct fundus
visualization.
Table 1 summarizes the evolution of mean Snellen
best-corrected visual acuity from the time of UM diag-
nosis to before and after PPV, correlating best-corrected
visual acuity with tumor location. Average visual
acuity evolved from 20/32 (20/2,000–20/20) at the
time of UM diagnosis till 20/200 (0–20/40) before
and 20/100 (0–20/25) after vitrectomy. Main causes
for loss of visual acuity at the time of UM diagnosis
were exudative RD and lens opacities. In this study,
visual acuity of 11 patients improved (52%), 5 patients
remained stable (24%), and 5 patients deteriorated
(24%) after PPV (Figure 2). Radiation retinopathy,
macular atrophy, and lens opacities were the main
causes preventing visual acuity from improving more
than to a mean of 20/100 after PPV.
Figure 3 shows the IOP evolution at the time of UM
diagnosis, before, immediately after, and 4 months
after vitrectomy, with mean IOP (in red) evolving
from 13 mmHg (±3 SD) at the time of diagnosis to
15 mmHg (±3 SD) preoperatively, 20 mmHg (±8 SD)
postoperatively, and 15 mmHg (±3 SD) 4 months
later. Seven patients presented a transient postopera-
tive rise in IOP above 21 mmHg of which 6 could be
normalized with medical treatment. One patient with
an inferotemporal anterior ciliochoroidal melanoma
received a Baerveldt tube into the anterior chamber
14 months after PPV for an epiretinal membrane
related to a “toxic tumor syndrome”7 with ﬁbrosis
and pupillary block.
Postoperative follow-up data showed that 4 of
our 21 patients developed phthisis bulbi (19%), 3 of
whom underwent secondary enucleation 33, 43, and
47 months after proton therapy (14%), respectively,
Table 2. Summarizes the Technical Variations on Standard PPV Applied During the First Vitrectomy and the
Corresponding Number of Patients, Including the Number of Phacoemulsiﬁcations and Intravitreal Injections of
Anti-VEFGs and Triamcinolone
First Vitrectomy Procedure Number +Phaco +Bevacizumab +Triamcinolone
2nd
PPV
3rd
PPV
Phthisis
Bulbi
Simple vitrectomy 10 1 1 2 1
Vitrectomy with silicone tamponade 1
Vitrectomy with air/gaz tamponnade 5
Vitrectomy with laserphotocoagulation 4 1 1 1 2
Vitrectomy with air tamponnade and
laserphotocoagulation
1 1 1 1 1 1
Total number 21 3 1 2 4 1 4
There were 4 patients requiring a second and one a third vitrectomy, 3 of whom developed phthisis bulbi.
Fig. 2. Graphic illustrating
the evolution of Snellen best-
corrected visual acuity (BCVA)
at the time of UM diagnosis as
well as before and after PPV for
each of the 21 operated patients
with mean visual acuity (red
line) evolving from 20/32, to
20/200 before, and 20/100 after
PPV, respectively. The only
patient with an inversed BCVA
curve evolving from hand
movements at diagnosis to 20/40
before and 20/100 after PPV had
an anterior UM complicated by
a dense VH at presentation, and
he underwent PPV when the
hemorrhage had already partially
resolved. At his postoperative
control examination, his sec-
ondary lens opacities had so
much increased that his BCVA
was lower than before PPV.
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and the fourth patient wearing a cosmetic contact lens.
Two belonged to the 7 patients with a postoperative
rise in IOP. All 4 were women who had undergone
vitrectomy, respectively, 6, 3, 5, and 3 months after
developing a dense VH. One was related to an anterior
tumor recurrence of an equatorial melanoma, treated
a second time by proton therapy. The other 3 patients
presented a posterior melanoma complicated by
uncontrollable proliferative radiation retinopathy, with
recurrent VHs, multiple interventions, and one of
whom developed neovascular glaucoma. Three of
21 patients presented liver metastases at 11, 24, and
54 months after proton therapy.
Discussion
This study assesses the role of VR surgery in
maximizing treatment outcome following complica-
tions after proton beam irradiation for UM. Analyzing
the indications, surgical technique, results, and safety
of VR surgery in the management of these complica-
tions, our study of 1,005 consecutive patients, treated
between January 2003 and August 2007, showed that
only 21 patients (2%) underwent VR surgery, illus-
trating why very few articles related to the subject
exist in the literature. It is interesting to note that
the majority of publications on this subject are
concerned with complications after plaque radiother-
apy or other conservative treatments. In contrast, data
on the surgical management of complications after
proton therapy are scarce.
Haimovici described 10 patients with UM present-
ing rhegmatogenous RD simultaneously to (n = 4) or
after (n = 6) radiation therapy (protons to iodine pla-
que ratio: 7:3). Only 1 of 10 had PPV and conse-
quently proton therapy, and the authors concluded
that because of the rare occurrence of rhegmatogenous
RD in patients with UM, the development of retinal
breaks and detachment was unlikely to be related to
the tumor or its treatment.10 The fact that our series
contains only one similar case conﬁrms that impres-
sion. In 2 recent publications, which addressed the role
of PPV performed on patients with UM after plaque
radiotherapy, 1 study showed that 74 patients of 3,707
(2%) had undergone vitrectomy because of VH, lead-
ing to complete resolution in 53 cases (72%).11 The
other study demonstrated that 29 patients of 3,841
treated UM eyes (0.8%) underwent PPV because of
proliferative radiation retinopathy.12 However, no fur-
ther details on these “PPV subgroups” are reported.
In a case series of 9 treated posterior UM patients
(7 with plaque and 2 with transpupillary thermother-
apy), Foster et al13 report a similar indication proﬁle as
ours: VH (n = 5), macular surgery (n = 3), and rheg-
matogenous RD (n = 1), with vitrectomy being
performed at a mean interval of 24.7 months (range,
7–47 months) after melanoma treatment, which is
about 4 months longer than our mean interval.
In general, the longer the interval since proton
therapy, the tougher the vitreous had become to cut
during PPV, although it is difﬁcult to translate this
observation into statistics. As a consequence, when-
ever VR surgery now becomes indicated, we tend to
intervene as soon as the tumor is locally controlled. In
5 cases, we enlarged our indication and performed
simultaneous cataract surgery to reestablish transpar-
ency of the visual axis. With a radiation threshold as
Fig. 3. Graphic showing IOP
evolution at the time of UM
diagnosis, before, immediately
after, and 4 months after PPV,
with a mean IOP (red line) of
13, 15, 20, and 15 mmHg,
respectively.
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low as 0.5 Gy for the induction of cataract to the
human lens, this is not surprising.14
Anti–vascular endothelial growth factors were
scarcely used in this case series, as most of these cases
were treated at a time when potential indications for
this kind of treatment were only slowly emerging.
Although one might speculate that increased use of
anti–vascular endothelial growth factors could poten-
tially prevent VH secondary to proliferative radiation
retinopathy in the future, it is more difﬁcult to imagine
how these treatments will signiﬁcantly reduce the
apparent mechanical effect of a rupture in the retinal
barrier. In this context, it is remarkable to note that in
our series 11 of 14 cases with VH requiring PPV also
presented a tumor breakthrough in the retina, whereas
melanomas with retinal invasion were reported to be
present in only 7% of a control UM population.11
Because of the multitude of factors inﬂuencing ﬁnal
visual acuity in UM eyes treated with radiotherapy and
consequently PPV, it is difﬁcult to draw universal
conclusions from a series of 21 eyes. Initial visual
acuity, tumor size and location, extent and duration of
the serous RD, radiation retinopathy, and/or neuropa-
thy are all factors that, on top of the other indications
for PPV (Table 1), will inﬂuence visual acuity after
PPV. However, the fact that average visual acuity
improved indicates that PPV had been justiﬁed in the
majority of our cases. Overall, anterior melanomas
appear to have a better visual outcome after PPV than
posterior melanomas because in the former, the poste-
rior pole has not been irradiated.
Regarding safety of PPV after plaque-irradiated
posterior UM, Bansal et al15 did not report an increased
risk of intraocular, local, orbital, or systemic dissemina-
tion of the tumor. Our series on PPV after proton ther-
apy indicates that postoperative IOP requires attention,
without being a permanent problem in most cases. With
a local tumor control after proton therapy of 98.8%,8
tumor recurrence at the entry ports does not appear to be
a problem, in contrast to patients undergoing PPV
before tumor treatment.16 However, the risk does need
to be taken into consideration in those cases where oph-
thalmoscopic or ultrasonographic tumor regression is
not convincing. The only case in this series, in which
tumor recurrence had been suspected before PPV, was
therefore immediately irradiated after surgery.
An interesting observation is that this series appears
to indicate that an eye with UM can only support
a limited number of surgical procedures before going
into phthisis bulbi. Of the 17 eyes treated once with
proton therapy, followed by one PPV, 16 eyes
survived, whereas of the 4 eyes having had more than
one PPV, only one eye, containing an anterior
melanoma, did not go into phthisis bulbi.
The fact that 3 patients developed distant metastases
is compatible with our overall Kaplan–Meyer survival
curve of UM treated with proton therapy.8
In conclusion, PPV after proton therapy is rarely
indicated (2% in our series). It is a safe procedure and
plays a role on 3 levels in the follow-up of patients with
UM. First, vitrectomy facilitates tumor surveillance
through reestablishing transparency of the visual axis.
Second, PPV increases the chances of eye retention as it
allows both panretinal photocoagulation to avoid neo-
vascular glaucoma and surgical repair of a rhegmatog-
enous detachment. And ﬁnally, macular surgery or
removal of a VH will increase visual acuity, especially
when the posterior pole has not been irradiated.
Vitreoretinal surgery does thus play an important role
in maximizing treatment outcome following complica-
tions after proton therapy for UM.
Key words: complications, intraocular pressure, mel-
anoma, proton therapy, radiotherapy, uveal melanoma,
visual acuity, vitreoretinal surgery, vitreous hemorrhage.
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